Bipolar vaporization: Do benefits outweigh risks?A large, randomized trial provides a head-to-head comparison of late complications involving the two approaches to BPH.
Best of AUA 2015: PCa surveillance, surgical controversies create buzzUrology Times’ “Best of AUA 2015” report provides a guide to the meeting’s take-home messages in 15 therapeutic areas—an information-packed, condensed summary of the top papers and presentations.
BPH technique efficacious even in severe obstructionA patient follow-up report shows promising mid-term results from five German urology centers that implemented the prostatic urethral lift (UroLift System, NeoTract, Inc.) to alleviate symptomatic BPH in patients suffering from mild, moderate, and even severe obstruction.
Study supports BPH laser’s use in high-risk menLaser photoselective vaporization prostatectomy using a 180W 532-nm lithium triborate laser (GreenLight XPS-180W laser system, American Medical Systems) is a safe and efficient option for treating BPH in men at high risk for surgical complications, according to findings from a large, international retrospective analysis.
Study uncovers 400% cost difference in BPH treatmentsThe study shows a wide discrepancy between the least and most expensive ways to treat the common prostate condition.
Embolization shows promise, wide applicability in BPHDespite a recent study’s promise, downsides to the procedure remain, according to one of the study’s authors.
Transfusion rate high with prostatectomy for BPHAnalyses of data from the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project are providing understanding on trends in utilization of simple prostatectomy for treatment of symptomatic BPH and addressing the gap in information about its outcomes.
Urethral lift's efficacy, safety sustained at 2 yearsUse of the urethral lift as a treatment for BPH provided rapid improvement in symptoms, flow, and quality of life that were sustained at 2 years in a multicenter study.
January 2015 Product Preview: FDA committee recommends approval of complicated UTI agentDrugs and devices in the pipeline from Actavis, Genomic Health, Lipella Pharmaceuticals, Polaris Group, Innocrin Pharmaceuticals, OncoGenex Pharmaceuticals, Heat Biologics, Repros Therapeutics, and Sophiris Bio.
CMS approves CPT codes for prostatic lift systemThe Centers for Medicare & Medicaid Services has approved two new Category I CPT codes for the UroLift system, a treatment for BPH, effective Jan. 1, 2015.